An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 Levels
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,132
- 主要终点
- Overall survival
研究概览
简要总结
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
详细描述
The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC)
- •Between January 2007 and June 2021 at Seoul National University Hospital
排除标准
- •Patients who had borderline resectable PDAC with arterial invasion
- •Patients who received chemotherapy as initial treatment and did not undergo surgery
- •Incomplete follow-up data for analysis
研究组 & 干预措施
resectable PDAC with no contact to major vessels (R-no contact)
干预措施: Neoadjuvant treatment (Drug)
resectable PDAC with contact PV/SMV of ≤180° (R-contact)
干预措施: Neoadjuvant treatment (Drug)
borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)
干预措施: Neoadjuvant treatment (Drug)
结局指标
主要结局
Overall survival
时间窗: From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months
the time from diagnosis to death from any cause or the date of the last visit
次要结局
未报告次要终点